Investigational agents for treatment of AIDS-related Kaposi's sarcoma

Expert Opinion on Investigational Drugs

Volumn 16, Issue 4, 2007, Pages 495-504

  Konstantinopoulos, Panagiotis A ^a   Sullivan, Ryan J ^a   Karamouzis, Michalis V ^b   Dezube, Bruce J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Angiogenesis inhibitors; Fumagillin; Human herpesvirus 8; IL 12 Kaposi's sarcoma; Imatinib; Kaposi's sarcoma associated herpesvirus; Matrix metalloprotease; Rapamycin; Thalidomide

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BMS 554417; BORTEZOMIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FOSCARNET; FUMAGILLOL CHLOROACETYLCARBAMATE; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON; GANCICLOVIR; GENISTEIN; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; SOMATOMEDIN C RECEPTOR; STEM CELL FACTOR RECEPTOR; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; BONE MARROW SUPPRESSION; CARCINOGENESIS; CELL GROWTH; CHILL; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG RESPONSE; DRUG TARGETING; FATIGUE; FEVER; FLU LIKE SYNDROME; HEMOLYTIC ANEMIA; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; KAPOSI SARCOMA; LIVER TOXICITY; LOW DRUG DOSE; MALIGNANT TRANSFORMATION; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; NONHUMAN; PHOTOSENSITIVITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN TARGETING; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SUPERINFECTION; URTICARIA; VIRUS CARCINOGENESIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTIVIRAL AGENTS; DRUGS, INVESTIGATIONAL; HUMANS; SARCOMA, KAPOSI;

EID: 34147165696     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.4.495     Document Type: Review

References (74)

1. DI LORENZO GD, KONSTANTINOPOULOS PA, PANTANOWITZ L, DI TROLIO RD, DE PLACIDO SD, DEZUBE BJ: Management of AIDS-related Kaposi's sarcoma. Lancet Oncol. (2007) 8(2):167-176.
2. MWANDA OW, FU P, COLLEA R, WHALEN C, REMICK SC: Kaposi's sarcoma in patients with and without human immunodeficiency virus infection, in a tertiary referral centre in Kenya. Ann. Trop. Med. Parasitol. (2005) 99:81-91.
3. SWIFT PS: The role of radiation therapy in the management of HIV-related Kaposi's sarcoma. Hematol. Oncol. Clin. North Am. (1996) 10:1069-1080.
4. GRESSEN EL, ROSENSTOCK JG, XIE Y, CORN BW: Palliative treatment of epidemic Kaposi sarcoma of the feet. Am. J. Clin. Oncol. (1999) 22:286-290.
5. WALMSLEY S, NORTHFELT DW, MELOSKY B, CONANT M, FRIEDMAN-KIEN AE, WAGNER B: Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J. Acquir. Immune Defic. Syndr. (1999) 22:235-246.
6. RAMIREZ-AMADOR V, ESQUIVEL-PEDRAZA L, LOZADA-NUR F et al.: Intralesional vinblastine versus 3% sodium tetradecyl sulfate for the treatment of oral Kaposi's sarcoma. A double blind, randomized clinical trial. Oral Oncol. (2002) 5:460-467.
7. NORTHFELT DW, DEZUBE BJ, THOMMES JA et al.: Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin and vincristine treatment of AIDS-related Kaposi's sarcoma. Results of a randomized Phase III clinical trial. J. Clin. Oncol. (1998) 16:2445-2451.
8. STEWART S, JABLONOWSKI N, GOEBEL FD et al.: Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J. Clin. Oncol. (1998) 16:683-691.
9. GILL PS, WERNZ J, SCADDEN DT et al.: Randomized Phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. (1996) 14:2353-2364.
10. WELLES L, FAVILLE MW, UETZAU J et al.: Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J. Clin. Oncol. (1998) 16:1112-1121.
11. TULPULE A, GROOPMAN, SEVILLE MW et al.: Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer (2002) 95:147-154.
12. KROWN SE: Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J. Clin. Oncol. (2004) 22:399-402.
13. SGADARI C, BARILLARI G, TOSCHI E et al.: HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat. Med. (2002) 8:225-232.
14. ENSOLI B, SIRIANNI MC: Kaposi's sarcoma pathogenesis: a link between immunology and tumor biology. Crit. Rev. Oncog. (1998) 9:107-124
15. DUPIN N, FISHER C, KELLAM P et al.: Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc. Natl. Acad. Sci. USA (1999) 96:4546-4551.
16. MESRI EA: Inflammatory reactivation and angiogenicity of Kaposi's sarcoma-associated herpesvirus/HHV8: a missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Blood (1999) 93:4031-4033.
17. CESARMAN E, NADOR RG, BAI F et al.: Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma. J. Virol. (1996) 70:8218-8223.
18. GUO HG, BROWNING P, NICHOLAS J et al.: Characterization of a chemokine receptor-related gene in human herpesvirus 8 and its expression in Kaposi's sarcoma. Virology (1997) 228:371-378.
19. GERSHENGORN MC, GERAS-RAAKA E, VARMA A, CLARK-LEWIS I: Chemokines activate Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor in mammalian cells in culture. J. Clin. Invest. (1998) 102:1469-1472.
20. GERAS-RAAKA E, VARMA A, CLARK-LEWIS I, GERSHENGORN MC: Kaposi's sarcoma-associated herpesvirus (KSHV) chemokine vMIP-II and human SDF-1α inhibit signaling by KSHV G protein-coupled receptor. Biochem. Biophys. Res. Commun. (1998) 253:725-727.
21. GERAS-RAAKA E, VARMA A, HO H et al.: Human interferon-γ-inducible protein 10 (IP-10) inhibits constitutive signaling of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. J. Exp. Med. (1998) 188:405-408.
22. ENSOLI B, BARILLARI G, SALAHUDDIN SZ, GALLO RC, WONG-STAAL F: Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature (1990) 345:84-86.
23. ENSOLI B, GENDELMAN R, MARKHAM P et al.: Synergy between basic fibroblast growth factor and HIV-1 tat protein in induction of Kaposi's sarcoma. Nature (1994) 371:674-680.
24. SODHI A, MONTANER S, GUTKIND JS: Viral hijacking of G-protein-coupled-receptor signalling networks. Nat. Rev. Mol. Cell. Biol. (2004) 5:998-1012.
25. TEE AR, FINGAR DC, MANNING BD et al.: Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl. Acad. Sci. USA (2002) 99:13571-13576.
26. YAO R, COOPER GM: Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science (1995) 267:2003-2006.
27. MANNING BD, TEE AR, LOGSDON MN et al.: Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/AKT pathway. Mol. Cell (2002) 10:151-162.
28. FUKADA T, HIBI M, YAMANAKA Y et al.: Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in antiapoptosis. Immunity (1996) 5:449-460.
29. VERMA A. KAMBHAMPATI S, PARMAR S, PLATANIAS LC: Jak family of kinases in cancer. Cancer Metastasis Rev. (2003) 22:423-434.
30. BURGER M, HARTMANN T, BURGER JA, SCHRAUFSTATTER I: KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway. Oncogene (2005) 24:2067-2075.
31. LUO JL, KAMATA H, KARIN M: IKK/NF-κB signaling: balancing life and death - a new approach to cancer therapy. J. Clin. Invest. (2005) 115:2625-2632.
32. VIATOUR P, MERVILLE MP, BOURS V, CHARIOT A: Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation. Trends Biochem. Sci. (2005) 30:43-52.
33. DADKE D, FRYER BH, GOLEMIS EA, FIELD J: Activation of p21-activated kinase 1-nuclear factor κB signaling by Kaposi's sarcoma-associated herpes virus G protein-coupled receptor during cellular transformation. Cancer Res. (2003) 63:8837-8847.
34. NICHOLAS J, RUVOLO VR, BURNS WH et al.: Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory prorein-1 and interleukin-6. Nat. Med. (1997) 3:287-292.
35. NEIPEL F, ALBRECHT JC, ENSSER A et al.: Human herpesvirus 8 encodes a homolog of interleukin-6. J. Virol. (1997) 71:839-842.
36. MULLBERG J, GEIB T, JOSTOCK T et al.: IL-6 receptor independent stimulation of human gp130 by viral IL-6. J. Immunol. (2000) 164:4672-4677.
37. HIDESHIMA T, CHAUHAN D, TEOH G et al.: Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6. Clin. Cancer Res. (2000) 6:1180-1189.
38. OSBORNE J, MOORE PS, CHANG Y: KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. Hum. Immunol. (1999) 60:921-927.
39. FOLPE AL, VEIKKOLA T, VALTOLA R, WEISS SW: Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheiomas, and a subset of angiosarcomas. Mod. Pathol. (2000) 13:180-185.
40. MASOOD R, CESARMAN E, SMITH DL et al.: Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor. Am. J. Pathol. (2002) 160:23-29.
41. SKOBE M, BROWN LF, TOGNAZZI K et al.: Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma. J. Invest. Dermatol. (1999) 113:1047-1053.
42. BAIS C, VAN GEELEN A, EROLES P et al.: Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR. Cancer Cell (2003) 3:131-143.
43. WANG L, WAKISAKA N, TOMLINSON CC et al.: The Kaposi's sarcoma-associated herpes virus (KSHV/HHV-8) K1 protein induces expression of angiogenic and invasion factors. Cancer Res. (2004) 64:2774-2781.
44. WANG L, DITTMER DP, TOMLINSON CC et al.: Immortilization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. Cancer Res. (2006) 66:3658-3666.
45. ZHANG X, WANG JF, CHANDRAN B et al.: Kaposi's sarcoma-associated herpesvirus activation of vascular endothelial growth factor receptor 3 alters endothelial function and enhances infection. J. Biol. Chem. (2005) 280:26216-26224.
46. CATRINA SB, LEWITT M, MASSAMBU C et al.: Insulin-like growth factor-I receptor activity is essential for Kaposi's sarcoma growth and survival. Br. J. Cancer (2005) 92:1467-1474.
47. CATRINA SB, BOTUSAN IR, RANTANEN A et al.: Hypoxia-inducible factor-1α and hypoxia-inducible factor-2α are expressed in Kaposi sarcoma and modulated by insulin-like growth factor. Clin. Cancer Res. (2006) 12:4506-4514.
48. PISTRITTO G, VENTURA L, MORES N et al.: Regulation of PDGF-B and PDGF receptor expression in the pathogenesis of Kaposi's sarcoma in AIDS. Antibiot. Chemother. (1994) 46:73-87.
49. STURZL M, ROTH WK, BROCKMEYER NH et al.: Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance. Proc. Natl. Acad. Sci. USA (1992) 89:7046-7050.
50. MOSES AV, JARVIS MA, RAGGO C et al.: Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J. Virol. (2002) 76:8383-8399.
51. BLANKAERT D, SIMONART T, VAN VOOREN JP et al.: Constitutive release of metalloproteinase-9 (92-kd type IV collagenase) by Kaposi's sarcoma cells. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (1998) 18:203-209.
52. IMPOLA U, CUCCURU MA, MASALA MV: Preliminary communication: matrix metalloproteinases in Kaposi's sarcoma. Br. J. Dermatol. (2003) 149:905-907.
53. LAFRENIE RM, WAHL LM, EPSTEIN JS: HIV-1-Tat modulates the function of monocytes and alters their interactions with microvessel endothelial cells. A mechanism of HIV pathogenesis. J. Immunol. (1996) 156:1638-1645.
54. KOON HB, BUBLEY GJ, PANTANOWITZ L et al.: Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J. Clin. Oncol. (2005) 23:982-989.
55. MORABITO A, DE MAIO E, DI MAIO M, NORMANNO N, PERRONE F: Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist (2006) 11(7):753-764.
56. LITTLE RF, WYVILL KM, PLUDA JM et al.: Activity of thalidomide in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. (2000) 18:2593-2602.
57. DEZUBE BJ, VON ROENN JH, HOLDEN-WILTSE J et al.: Fumagillin analog in the treatment of Kaposi's sarcoma: a Phase I AIDS Clinical Trial Group study. J. Clin. Oncol. (1998) 16:1444 1449.
58. HIDALGO M, ECKHARDT SG: Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. (2001) 93:178-193.
59. DEZUBE BJ, KROWN SE, LEE JY, BAUER KS, ABOULAFIA DM: Randomized Phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J. Clin. Oncol. (2006) 24:1389-1394.
60. STALLONE G, SCHENA A, INFANTE B et al.: Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N. Engl. J. Med. (2005) 352(13):1317-1323.
61. KREUTERA, RASOKAT H, KLOUCHE M et al.: Liposomal pegylated doxorubicin versus low-dose recombinant interferon alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers. Cancer Invest. (2005) 23:653-659.
62. BRUNDA MJ: Interleukin-12. J. Leukoc. Biol. (1994) 55:280-288.
63. + T lymphocytes. J. Immunol. (1993) 151:2444-2452.
64. BRUNDA MJ, LUISTRO I., WARRIER RR et al.: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med (1993) 178:1223-1230.
65. NASTALA CL, EDINGTON HD, MCKINNEY TG et al.: Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. (1994) 153:1697-1706.
66. VOEST EE, KENYON BM, O'REILLY MS, TRUITT G, D'AMATO RJ, FOLKMAN J: Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. (1995) 87:581-586.
67. ANGIOLILLO AL, SGADARI C, TAUB DD et al.: Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med (1995) 182:155-162.
68. SGADARI C, ANGIOLILLO AL, TOSATO G: Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood (1996) 87:3877-3882.
69. CLERICI M, LUCEY DR BERZOFSKY JA et al.: Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science (1993) 262:1721-1724.
70. CHOUGNET C, WYNN TA, CLERICI M et al.: Molecular analysis of decreased interleukin-12 production in persons infected with human immunodeficiency virus. J. Infect. Dis. (1996) 174:46-53.
71. LITTLE RF, PLUDA JM, WYVILL KM et al.: Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood (2006) 107(12):4650-4657.
72. KIM EJ, SHIN HK, PARK JH: Genistein inhibits insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells: a possible mechanism of the growth inhibitory effect of genistein. J. Med. Food (2005) 8:431-438.
73. HALUSKA P, CARBONI JM, LOEGERING DA et al.: In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/ insulin receptor inhibitor, BMS-554417. Cancer Res. (2006) 66:362-371.
74. GLESBY MJ, HOOVER DR, WENG S et al.: Use of andherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J. Infect. Dis. (1996) 173:1477-1480.